Therapy in ST-elevation myocardial infarction: Reperfusion strategies, pharmacology and stent

Vikas Singh, Mauricio G. Cohen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The estimated annual incidence of new and recurrent myocardial infarction (MI) in the U.S. is 715,000 events. Primary percutaneous coronary intervention (PCI) is the reperfusion strategy of choice in most patients with acute ST-elevation myocardial infarction (STEMI). Recent advances in percutaneous techniques and devices, including manual aspiration catheters and newer generation drug eluting stents and pharmacologic therapies, such as novel antiplatelets and anticoagulants have led to significant improvements in the acute and long-term outcomes for these patients. Implementation of community-wide systems directed to shorten treatment times tied to closelymonitored quality improvement processeshave led to further advances in STEMI care. Recent data suggests that transradial access for primary PCI is associated with improved outcomes. This contemporary review discusses the strategies for reperfusion, pharmacological therapy and stent selection process involved in STEMI.

Original languageEnglish (US)
Article number302
JournalCurrent Treatment Options in Cardiovascular Medicine
Issue number5
StatePublished - May 2014


  • Coronary stents
  • Myocardial infarction
  • Primary percutaneous coronary intervention
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Therapy in ST-elevation myocardial infarction: Reperfusion strategies, pharmacology and stent'. Together they form a unique fingerprint.

Cite this